The document announces a dinner lecture on using hypomethylating agents to treat myelodysplastic syndromes. The event will feature an international speaker, Dr. Antonio Pinto from Italy, who will discuss treatment schedules and preventing side effects. It provides details on the date, time, venue, speaker biography and contact information to RSVP for the buffet dinner.

2. Cordially invites you to attend a Dinner Lecture
“How to use Hypomethylating Agent in Patients with MDS:
Focus on Treatment Schedule and Prevention of Side Effect”
International Speaker Chairperson
Dr Antonio Pinto Dato’ Dr Chang Kian Meng
Head, Hematology/Oncology Unit Head, Department of Haematology
National Cancer Institute Hospital Ampang
Fondazione ‘Pascale’ President
Head, Department of Hematology Malaysian Society of Haematology
Istituto Pascale
IRCCS, Naples, Italy
Date: March 8, 2011
(Tuesday)
Time: 1900- 2200 hrs
Venue: Hilton Kuala Lumpur
Suite 2 & 3, Level 7
Dr. Antonio Pinto graduated in Medicine in 1981 and obtained the Specialty Board Certification in Oncology and
in Clinical Hematology. He gained clinical and research experience during different training periods in
Oncology/Hematology in the UK (University of London, St. Thomas’ Hospital, Northwick Park Hospital;
University of Glasgow) and Australia (University of Melbourne, Ludwig Institute for Cancer Research). Dr. Pinto
joined in 1987 the Centro di Riferimento Oncologico, Aviano, Italy where he served as Head of the
Developmental Oncology/Hematology and Leukemia Unit up to November 2000. From December 2000 to date,
he is serving as Head of the Hematology/Oncology Unit of the National Cancer Institute, Fondazione ‘Pascale’,
IRCCS, Naples, Italy. Starting from march 2008 he was appointed as Head of the new Department of
Hematology at the Istituto Pascale, IRCCS, Naples, Italy. Dr. Pinto has published several studies addressing the
relevance of cell contact-dependent and cytokine-mediated interactions between Reed-Sternberg cells and
reactive cell populations in tissues involved by Hodgkin’s disease.
He has also unveiled the role of some TNF-superfamily receptors and ligands and of CD138 (Syndecan-1) in
human leukemias and Hodgkin’s lymphoma. He concurrently coordinated the clinical development in Europe of
DNA-methyltransferases inhibitor 5-aza-2’-deoxycytidine (Decitabine) by designing and conducting phase I and
II trials in leukemia and myelodysplastic syndromes, becaming member of the international working group (IWG)
for response criteria in myelodysplasia. Dr. Pinto currently coordinates phase II trials on newer upfront and
salvage regimes for Hodgkin’s and non-Hodgkin lymphoma and GCP phase III studies with upfront experimental
regimes in lymphomas and multiple myeloma. He acted as member of the National Comittee for Evaluation of
Supported by an
Phase I Clinical Trials (Commissione Ministeriale per l'accertamento dei requisiti dei prodotti farmaceutici di
educational
nuova istituzione, ex art.7 D.P.R. 439/2001) and of the Working Party for non conventional cancer treatments, grant from
Consiglio Superiore di Sanità, National Ministry of Health, Rome, Italy. Dr. Pinto authored more than 160 papers
on high-rank international journals, with a personal IF > 650.
Buffet Dinner will be provided. Limited seats available.
• RSVP • by March 01, 2011 •
Wong Chee Keong: +65 9177 4866 / ckwong@celgene.com •
• Juls: +65 6572 5131 / jbjalil@celgene.com •

3. SPEAKER AND TITLE TIME
Registration 19:00-19:30
DR ANTONIO PINTO
How to use Hypomethylating Agent in Patients with MDS: 19:30-20:10
Focus Treatment Schedule and Prevention of Side Effect
Q&A 20:10-20:30
20:30
DINNER
onwards